The costs of nosocomial resistant gram negative intensive care unit infections among patients with the systemic inflammatory response syndrome- a propensity matched case control study

详细信息    查看全文

• 作者：Anupama Vasudevan (1)
  Babar Irfan Memon (2)
  Amartya Mukhopadhyay (3)
  Jialiang Li (4)
  Paul Ananth Tambyah (5)
  
  1. Yong Loo Lin School of Medicine ; National University of Singapore ; 10 Medical Drive ; Singapore ; 117597 ; Singapore
  2. Steward Carney Hospital ; Tufts University School of Medicine ; 136 Harrison Avenue ; Boston ; MA ; 02110 ; USA
  3. Division of Respiratory and Critical Care Medicine ; National University Health System ; 1E Kent Ridge Road ; Singapore ; 119228 ; Singapore
  4. Department of Statistics and Applied Probability ; National University of Singapore ; Faculty of Science ; 6 Science Drive 2 ; Singapore ; 119077 ; Singapore
  5. Division of Infectious Diseases ; National University Health System ; 1E Kent Ridge Road ; Singapore ; 119228 ; Singapore
  
• 关键词：Resistant gram negative infection ; Sensitive gram negative infection ; Critically ill patient ; ICU ; Costs
• 刊名：Antimicrobial Resistance and Infection Control
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：4
• 期：1
• 全文大小：456 KB
• 参考文献：1. Donowitz LG, Wenzel RP, Hoyt JW. High risk of hospital-acquired infection in the ICU patient. Crit Care Med. 1982;10:355鈥?. CrossRef
  2. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011;1:47. CrossRef
  3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1鈥?2. CrossRef
  4. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848鈥?4. CrossRef
  5. Van Duijn PJ, Dautzenberg MJD, Oostdijk EAN. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care. 2011;17(6):658鈥?5. CrossRef
  6. Clark NM, Patterson J, Lynch JP. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care. 2003;9:413鈥?3. CrossRef
  7. Hsu L-Y, Tan T-Y, Jureen R, Koh T-H, Krishnan P, Tzer-Pin Lin R, et al. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis. 2007;13:1944鈥?. CrossRef
  8. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009;9:417鈥?2. CrossRef
  9. Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;55:807鈥?5. CrossRef
  10. Webb M, Riley LW, Roberts RB. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis. 2001;33:445鈥?2. CrossRef
  11. Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of Gram-negative resistance. Crit Care Med. 2007;35:89鈥?5. CrossRef
  12. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. 2009;37:1463鈥?. CrossRef
  13. Rosenbaum PR. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41鈥?5. CrossRef
  14. D鈥橝gostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265鈥?1. CrossRef
  15. Vasudevan A, Chuang L, Jialiang L, Mukhopadhyay A, Goh EY-Y, Tambyah PA. Inappropriate empirical antimicrobial therapy for multidrug-resistant organisms in critically ill patients with pneumonia is not an independent risk factor for mortality: results of a prospective observational study of 758 patients. J Glob Antimicrob Resist. 2013;1:123鈥?0. CrossRef
  16. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268鈥?1. CrossRef
  17. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128鈥?0. CrossRef
  18. Vasudevan A, Mukhopadhyay A, Li J, Yuen E, Tambyah P. A prediction tool for nosocomial multi-drug resistant gram-negative bacilli infections in critically ill patients - prospective observational study. BMC Infect Dis. 2014;14:615. CrossRef
  19. Cooper LM, Linde-Zwirble WT. Medicare intensive care unit use: analysis of incidence, cost, and payment. Crit Care Med. 2004;32:2247鈥?3.
  20. Daxboeck F, Budic T, Assadian O, Reich M, Koller W. Economic burden associated with multi-resistant Gram-negative organisms compared with that for methicillin-resistant Staphylococcus aureus in a university teaching hospital. J Hosp Infect. 2006;62:214鈥?. CrossRef
  21. Horcajada JP, Belvis F, Castells X, Grau S, Riu M, Morales E, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122. CrossRef
  22. Lee N-Y, Lee H-C, Ko N-Y, Chang C-M, Shih H-I, Wu C-J, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28:713鈥?. CrossRef
  23. Wilson SJ, Knipe CJ, Zieger MJ, Gabehart KM, Goodman JE, Volk HM, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control. 2004;32:342鈥?. CrossRef
  24. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162鈥?1. CrossRef
  25. Ng E, Earnest A, Lye DC, Ling ML, Ding Y, Hsu LY. The excess financial burden of multidrug resistance in severe gram-negative infections in Singaporean hospitals. Ann Acad Med Singapore. 2012;41:189鈥?3.
  26. Piddock LJ. Antibiotic action: helping deliver action plans and strategies. Lancet Infect Dis. 2013;13:1009鈥?1. CrossRef
  27. Public Health Action Plan to Combat Antimicrobial Resistance [http://www.cdc.gov/drugresistance/itfar/introduction_overview.html]
  28. Strategies for global surveillance of antimicrobial resistance [http://www.who.int/drugresistance/publications/surveillance-meeting2012/en/index.html]
  29. Joint Conference on Antimicrobial Resistance: State of Play of the 5-year action plan [http://ec.europa.eu/health/antimicrobial_resistance/events/ev_11122013_en.htm]
  30. The evolving threat of antimicrobial resistance - options for action [http://www.who.int/patientsafety/implementation/amr/publication/en/index.html]
  31. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954鈥?1. CrossRef
  32. Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis. 2011;53 Suppl 2:S33鈥?5. quiz S56鈥?. CrossRef
  33. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27:1226鈥?2. CrossRef
  34. Roberts RR, Hota B, Ahmad I, Scott RD, Foster SD, Abbasi F, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175鈥?4. CrossRef
  
• 刊物主题：Medical Microbiology; Drug Resistance; Infectious Diseases;
• 出版者：BioMed Central
• ISSN：2047-2994

文摘

Background Infections due to multi-drug resistant gram negative bacilli (RGNB) in critically ill patients have been reported to be associated with increased morbidity and costs and only a few studies have been done in Asia. We examined the financial impact of nosocomial RGNB infections among critically ill patients in Singapore. Methods A nested case control study was done for patients at medical and surgical ICUs of a tertiary university hospital (August 2007-December 2011) matched by propensity scores. Two groups of propensity-matched controls were selected for each case patient with nosocomial drug resistant gram negative infection: at-risk patients with no gram negative infection or colonization (Control A) and patients with ICU acquired susceptible gram negative infection (SGNB) (Control B). The costs of the hospital stay, laboratory tests and antibiotics prescribed as well as length of stay were compared using the Wilcoxon matched-pairs signed rank test. Results Of the 1539 patients included in the analysis, 76 and 65 patients had ICU acquired RGNB and SGNB infection respectively. The median(range) total hospital bill per day for patients with RGNB infection was 1.5 times higher than at-risk patients without GNB infection [Singapore dollars 2637.8 (458.7-20610.3) vs. 1757.4 (179.9-6107.4), p0.0001]. The same trend was observed when compared with SGNB infected patients. The median costs per day of antibiotics and laboratory investigations were also found to be significantly higher for patients with RGNB infection. The length of stay post infection was not found to be different between those infected with RGNB and SGNB. Conclusion The economic burden of RGNB infections to the patients and the hospital is considerable. Efforts need to be taken to prevent their occurrence by cost effective infection control practices.